More Information

Ontak outdoes placebo in phase III trial for some CTCL (MF & Sezary) patients

Results from a multi-center phase III trial examiniing the safety and efficacy of two doses of denileukin diftitox (Ontak) in patients with biopsy-confirmed CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including both mycosis fungoides and Sezary Syndrome suggest merely that this recombinant protein can outperform a placebo.

Participating patients had received at least three prior therapies, and the trial's primary end point was overall response rate, meaning the total number of patients who responded to the therapy, to any degree.

For patients getting the denileukin diftitox, the ORR was 44%. Placebo, 15.9%.

Researcher's conclusion: "Denileukin diftitox had a significant and durable effect on ORR and PFS with an acceptable safety profile in patients with early- and late-stage CTCL".

By Ross Bonander

Sources:
- Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma
- HemOncToday

»
 
disclaimer

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
More Information
support groups

SupportGroups.com is for individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Latest Blog Entries
User login
Poll
What is most important to you in an Online Support Group?:
Did You Know?

Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Improved diagnosis has contributed greatly to the increase as doctors better understand cancer of lymphocytes and can distinguish it from other diseases.
lymphomas